NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/28/23 | DEF 14A | Definitive proxy statements |
|
58 | |
| 03/31/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
113 |
| 03/29/23 | 8-K | Current report filing |
|
|
7 |
| 03/01/23 | 4/A | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/23/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/17/23 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
9 | |
| 02/17/23 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
11 | |
| 01/31/23 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 01/26/23 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/24/23 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |